MorphoSys AG buy piccolo90
Start price
28.04.16
/
50%
€44.85
Target price
12.07.16
€62.28
Performance (%)
-11.51%
End price
12.07.16
€39.69
Summary
This prediction ended on 12.07.16 with a price of €39.69. The price of MorphoSys AG has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.51%. piccolo90 has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | 1.647% | 1.647% | 221.496% | -0.818% |
| iShares Core DAX® | 1.662% | 4.835% | 17.361% | 19.329% |
| iShares Nasdaq 100 | 0.667% | 0.000% | 38.234% | 55.157% |
| iShares Nikkei 225® | -2.139% | -4.786% | 13.099% | 7.393% |
| iShares S&P 500 | 0.564% | 0.775% | 29.181% | 46.527% |
Comments by piccolo90 for this prediction
In the thread Morphosys AG diskutieren
piccolo90 stimmt der Outperform-Einschätzung der institutionellen Analysten zu
piccolo90 stimmt am 28.04.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 62.28€ zu.
(Vom Mitglied beendet)